| 0.0002 -0.001 (-84.62%) | 01-04 13:45 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Humanigen, Inc. is a clinical-stage biopharmaceutical firm primarily focused on addressing and mitigating an exacerbated immune response termed "cytokine storm." At the forefront of its therapeutic efforts is lenzilumab, an antibody engineered to bind with and neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is heavily invested in advancing lenzilumab as a treatment for cytokine storm associated with COVID-19; it has successfully completed a crucial Phase 3 study and is concurrently participating in an NIH-sponsored Phase 2/3 investigation for this indication. Beyond COVID-19, lenzilumab's utility is being explored in combination with CD19-targeted CAR-T cell therapies. Its potential also extends to other inflammatory disorders such as acute Graft versus Host Disease in individuals undergoing allogeneic hematopoietic stem cell transplantation, as well as eosinophilic asthma and rheumatoid arthritis. Moreover, Humanigen is examining lenzilumab for chronic myelomonocytic leukemia patients who exhibit RAS pathway mutations. Humanigen's pipeline further comprises two other proprietary Humaneered monoclonal antibodies. Ifabotuzumab, which targets EphA3, completed a Phase 1 study for glioblastoma multiforme, demonstrating precise targeting of all known tumor locations without affecting healthy tissues. The second, HGEN005, designed to target EMR1, is being investigated for various eosinophilic conditions, including eosinophilic leukemia, both as an optimized standalone antibody and as a foundational element for a new CAR-T therapy. Founded in 2000, Humanigen, Inc. operates from its headquarters in Short Hills, New Jersey.
Sat, 26 Apr 2025
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement - ACCESS Newswire
Mon, 01 Jul 2024
Taran Therapeutics, Inc. agreed to acquire Assets of Humanigen, Inc. for $20 million. - marketscreener.com
Fri, 05 Jan 2024
HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy - InvestorPlace
Fri, 09 Jun 2023
PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia - News-Medical
Mon, 29 Aug 2022
Why Is Humanigen (HGEN) Stock Down 16% Today? - InvestorPlace
Thu, 28 Oct 2021
Korn/Ferry International Share Price - KFY, RNS News, Articles, Quotes, & Charts (NYSE:KFY) - Proactive financial news
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|